Stay updated on FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.

Latest updates to the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedAdded a dedicated Locations section with site entries in Georgia, New York, Texas, Washington, and Ontario, and updated the page revision to v3.3.3. Removed the older HHS Vulnerability Disclosure link and the prior location sections tied to revision v3.3.2.SummaryDifference0.4%

- Check26 days agoNo Change Detected
- Check48 days agoChange DetectedAdded a note that PubMed publications are automatically filled in from PubMed and updated the page revision to v3.3.2 (replacing v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check55 days agoChange DetectedRemoved the government funding/operating status notice banner from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check69 days agoChange DetectedNo significant changes detected on the study details page; the core information and layout remain as previously shown. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check98 days agoChange DetectedUpdated the page to v3.2.0 with a prominent notice about potential data/tansaction delays due to funding gaps and where to check operating status; previous v3.1.0 reference removed.SummaryDifference3%

- Check106 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0. No substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FIDES-02: Derazantinib & Atezolizumab in Urothelial Cancer Clinical Trial page.